Renal cell carcinoma articles from across Nature Portfolio

COSMIC-313 combines all of the approved drugs against actionable targets in renal cell carcinoma into one triplet regimen. Although this approach has greater clinical efficacy than one of the standard-of-care doublet therapies, toxicities can limit adequate drug administration and, thus, we argue that this regimen should not yet be adopted. We also discuss ongoing investigations of other triplet regimens.

Several newly approved therapies have substantially altered the treatment paradigm for multiple genitourinary cancers. Considering the existence of numerous possible treatment approaches, understanding which treatment attributes are most valued by each patient is crucial to physicians to recommend a cancer-directed treatment.

The cellular action of SARS-CoV-2, the virus responsible for the COVID-19 global pandemic, is dependent on a specific combination of receptors and cofactors. These proteins are now known to be expressed in normal kidney tubule tissue and renal cell carcinoma cells, representing possible targets for budding therapeutic modalities.